ID: ALA2337010

Max Phase: Preclinical

Molecular Formula: C142H205N35O35

Molecular Weight: 2962.41

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCNC(=O)CCCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CO)C(C)C)C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CO)C(=O)O

Standard InChI:  InChI=1S/C142H205N35O35/c1-74(2)58-100(165-131(202)105(164-122(193)94(144)70-178)64-86-66-152-95-28-17-15-26-92(86)95)126(197)157-81(12)120(191)170-107(63-85-42-50-91(185)51-43-85)139(210)177-57-25-33-111(177)135(206)154-68-114(187)156-79(10)121(192)174-117(77(7)8)138(209)172-108(71-179)133(204)167-103(61-83-38-46-89(183)47-39-83)129(200)162-98(31-22-54-150-141(145)146)124(195)160-97(30-19-21-53-149-113(186)35-14-13-20-52-143)123(194)161-99(32-23-55-151-142(147)148)125(196)166-104(62-84-40-48-90(184)49-41-84)130(201)171-109(72-180)134(205)175-116(76(5)6)137(208)159-78(9)118(189)155-69-115(188)176-56-24-34-112(176)136(207)169-102(60-82-36-44-88(182)45-37-82)127(198)158-80(11)119(190)163-101(59-75(3)4)128(199)168-106(132(203)173-110(73-181)140(211)212)65-87-67-153-96-29-18-16-27-93(87)96/h15-18,26-29,36-51,66-67,74-81,94,97-112,116-117,152-153,178-185H,13-14,19-25,30-35,52-65,68-73,143-144H2,1-12H3,(H,149,186)(H,154,206)(H,155,189)(H,156,187)(H,157,197)(H,158,198)(H,159,208)(H,160,195)(H,161,194)(H,162,200)(H,163,190)(H,164,193)(H,165,202)(H,166,196)(H,167,204)(H,168,199)(H,169,207)(H,170,191)(H,171,201)(H,172,209)(H,173,203)(H,174,192)(H,175,205)(H,211,212)(H4,145,146,150)(H4,147,148,151)/t78-,79-,80-,81-,94-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,116-,117-/m0/s1

Standard InChI Key:  FIKIMEKCDPWXON-KHPWIGICSA-N

Associated Targets(Human)

Ephrin type-A receptor 4 2022 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Ephrin type-B receptor 2 1899 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Ephrin type-A receptor 2 3499 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 2962.41Molecular Weight (Monoisotopic): 2960.5337AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Duggineni S, Mitra S, Lamberto I, Han X, Xu Y, An J, Pasquale EB, Huang Z..  (2013)  Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor.,  (3): [PMID:24167659] [10.1021/ml3004523]

Source